{"id":5294,"date":"2024-04-07T22:53:20","date_gmt":"2024-04-07T14:53:20","guid":{"rendered":"https:\/\/flcube.com\/?p=5294"},"modified":"2024-10-13T18:48:43","modified_gmt":"2024-10-13T10:48:43","slug":"eisai-forges-strategic-partnership-with-china-resource-medicine-and-china-resources-sanjiu-for-pharmaceutical-collaboration","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=5294","title":{"rendered":"Eisai Forges Strategic Partnership with China Resource Medicine and China Resources Sanjiu for Pharmaceutical Collaboration"},"content":{"rendered":"\n

Japanese pharmaceutical company Eisai (TYO: 4523<\/a>) has entered into a cooperation agreement with China Resource Medicine Commercial Holdings Ltd. and China Resources Sanjiu Medical & Pharmaceutical Co. Ltd. The partnership aims to expand and unite efforts to carry out in-depth cooperation in traditional medicine, innovative projects, patient management, internet healthcare, and other fields. This alliance is designed to enhance the service value of the three parties within the pharmaceutical industry.<\/p>\n\n\n\n

Eisai’s Stronger Neo-Minophagen C (SNMC, compound glycyrrhizin), developed by Japan-based Minophagen, received marketing approval in China in 2000. SNMC is an injectable preparation of Glycyrrhizin, extracted from the saponin component found in the roots of the licorice plant, used to improve abnormal hepatic function in patients with chronic hepatic diseases.<\/p>\n\n\n\n

In July 2007, Eisai secured a licensing deal with Minophagen, gaining exclusive development and marketing rights to the drug in Japan and Eurasian countries and regions where the drug was not yet commercially available. For countries and regions in Eurasia where the drug was already on the market, Eisai obtained exclusive priority negotiation rights. On April 1, 2009, Eisai took over marketing activities for the drug in the Chinese market.<\/p>\n\n\n\n

This strategic partnership with China Resource Medicine and China Resources Sanjiu is expected to leverage Eisai’s pharmaceutical expertise and the resources of its Chinese partners to broaden the reach and impact of their pharmaceutical offerings, particularly in the areas of traditional medicine and digital healthcare.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Japanese pharmaceutical company Eisai (TYO: 4523) has entered into a cooperation agreement with China Resource…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[350,1151],"class_list":["post-5294","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-eisai","tag-tyo-4523"],"yoast_head":"\nEisai Forges Strategic Partnership with China Resource Medicine and China Resources Sanjiu for Pharmaceutical Collaboration - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Japanese pharmaceutical company Eisai (TYO: 4523) has entered into a cooperation agreement with China Resource Medicine Commercial Holdings Ltd. and China Resources Sanjiu Medical & Pharmaceutical Co. Ltd. The partnership aims to expand and unite efforts to carry out in-depth cooperation in traditional medicine, innovative projects, patient management, internet healthcare, and other fields. This alliance is designed to enhance the service value of the three parties within the pharmaceutical industry.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=5294\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eisai Forges Strategic Partnership with China Resource Medicine and China Resources Sanjiu for Pharmaceutical Collaboration\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=5294\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-04-07T14:53:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-13T10:48:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5294#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5294\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eisai Forges Strategic Partnership with China Resource Medicine and China Resources Sanjiu for Pharmaceutical Collaboration\",\"datePublished\":\"2024-04-07T14:53:20+00:00\",\"dateModified\":\"2024-10-13T10:48:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5294\"},\"wordCount\":250,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Eisai\",\"TYO: 4523\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=5294#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5294\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=5294\",\"name\":\"Eisai Forges Strategic Partnership with China Resource Medicine and China Resources Sanjiu for Pharmaceutical Collaboration - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-04-07T14:53:20+00:00\",\"dateModified\":\"2024-10-13T10:48:43+00:00\",\"description\":\"Japanese pharmaceutical company Eisai (TYO: 4523) has entered into a cooperation agreement with China Resource Medicine Commercial Holdings Ltd. and China Resources Sanjiu Medical & Pharmaceutical Co. Ltd. The partnership aims to expand and unite efforts to carry out in-depth cooperation in traditional medicine, innovative projects, patient management, internet healthcare, and other fields. This alliance is designed to enhance the service value of the three parties within the pharmaceutical industry.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5294#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=5294\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=5294#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eisai Forges Strategic Partnership with China Resource Medicine and China Resources Sanjiu for Pharmaceutical Collaboration\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eisai Forges Strategic Partnership with China Resource Medicine and China Resources Sanjiu for Pharmaceutical Collaboration - Insight, China's Pharmaceutical Industry","description":"Japanese pharmaceutical company Eisai (TYO: 4523) has entered into a cooperation agreement with China Resource Medicine Commercial Holdings Ltd. and China Resources Sanjiu Medical & Pharmaceutical Co. Ltd. The partnership aims to expand and unite efforts to carry out in-depth cooperation in traditional medicine, innovative projects, patient management, internet healthcare, and other fields. This alliance is designed to enhance the service value of the three parties within the pharmaceutical industry.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=5294","og_locale":"en_US","og_type":"article","og_title":"Eisai Forges Strategic Partnership with China Resource Medicine and China Resources Sanjiu for Pharmaceutical Collaboration","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=5294","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-04-07T14:53:20+00:00","article_modified_time":"2024-10-13T10:48:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=5294#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=5294"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eisai Forges Strategic Partnership with China Resource Medicine and China Resources Sanjiu for Pharmaceutical Collaboration","datePublished":"2024-04-07T14:53:20+00:00","dateModified":"2024-10-13T10:48:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=5294"},"wordCount":250,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Eisai","TYO: 4523"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=5294#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=5294","url":"https:\/\/flcube.com\/?p=5294","name":"Eisai Forges Strategic Partnership with China Resource Medicine and China Resources Sanjiu for Pharmaceutical Collaboration - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-04-07T14:53:20+00:00","dateModified":"2024-10-13T10:48:43+00:00","description":"Japanese pharmaceutical company Eisai (TYO: 4523) has entered into a cooperation agreement with China Resource Medicine Commercial Holdings Ltd. and China Resources Sanjiu Medical & Pharmaceutical Co. Ltd. The partnership aims to expand and unite efforts to carry out in-depth cooperation in traditional medicine, innovative projects, patient management, internet healthcare, and other fields. This alliance is designed to enhance the service value of the three parties within the pharmaceutical industry.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=5294#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=5294"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=5294#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eisai Forges Strategic Partnership with China Resource Medicine and China Resources Sanjiu for Pharmaceutical Collaboration"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/5294","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5294"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/5294\/revisions"}],"predecessor-version":[{"id":5994,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/5294\/revisions\/5994"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5294"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5294"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5294"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}